Literature DB >> 28160462

Knockdown of TRIM44 Inhibits the Proliferation and Invasion in Prostate Cancer Cells.

Yuying Tan, Hanxin Yao, Jinghai Hu, Lingyun Liu.   

Abstract

Tripartite motif 44 (TRIM44), a member of the TRIM protein family, has been shown to play a role in tumor development and progression. However, the potential involvement of TRIM44 in prostate cancer has not been fully explored. Therefore, in the present study, we analyzed the expression of TRIM44 in prostate cancer and assessed the role of TRIM44 in the progression of prostate cancer. Our results showed that the expression of TRIM44 was significantly upregulated in human prostate cancer cell lines. In addition, knockdown of TRIM44 significantly inhibited the proliferation, migration, and invasion of prostate cancer cells in vitro, as well as attenuated the tumor growth in vivo. Mechanistic studies showed that knockdown of TRIM44 significantly reduced the levels of phosphorylated PI3K and Akt in PC-3 cells. In conclusion, this study provided evidence that knockdown of TRIM44 inhibited proliferation and invasion in prostate cancer cells, at least in part, through the inactivation of the PI3K/Akt signaling pathway. These results suggest that TRIM44 may be a potential therapeutic target for the treatment of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28160462     DOI: 10.3727/096504017X14854310794561

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  14 in total

Review 1.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

2.  Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer.

Authors:  Shuang Liu; Hexuan Yin; Hongying Ji; Jiaqi Zhu; Rong Ma
Journal:  Exp Ther Med       Date:  2018-07-30       Impact factor: 2.447

3.  High TRIM44 expression as a valuable biomarker for diagnosis and prognosis in cervical cancer.

Authors:  Shuang Liu; Fanling Meng; Jing Ding; Hongying Ji; Mu Lin; Jiaqi Zhu; Rong Ma
Journal:  Biosci Rep       Date:  2019-03-06       Impact factor: 3.840

Review 4.  E3 Ubiquitin Ligase TRIM Proteins, Cell Cycle and Mitosis.

Authors:  Santina Venuto; Giuseppe Merla
Journal:  Cells       Date:  2019-05-27       Impact factor: 6.600

5.  TRIM44 Promotes Colorectal Cancer Proliferation, Migration, and Invasion Through the Akt/mTOR Signaling Pathway.

Authors:  Chun-Guang Li; Hang Hu; Xiao-Jun Yang; Chao-Qun Huang; Xue-Qiao Yu
Journal:  Onco Targets Ther       Date:  2019-12-09       Impact factor: 4.147

6.  miR-192-5p suppresses the progression of lung cancer bone metastasis by targeting TRIM44.

Authors:  Peng Zou; Menghai Zhu; Chong Lian; Jiaqiang Wang; Zhiquan Chen; Xiaoming Zhang; Yongchao Yang; Xinfeng Chen; Xinhui Cui; Jijun Liu; Hexuan Wang; Qi Wen; Ji Yi
Journal:  Sci Rep       Date:  2019-12-23       Impact factor: 4.379

7.  TRIM44 mediated p62 deubiquitination enhances DNA damage repair by increasing nuclear FLNA and 53BP1 expression.

Authors:  Lin Lyu; Tsung-Chin Lin; Nami McCarty
Journal:  Oncogene       Date:  2021-07-01       Impact factor: 9.867

8.  TRIM44 Is a Poor Prognostic Factor for Breast Cancer Patients as a Modulator of NF-κB Signaling.

Authors:  Hidetaka Kawabata; Kotaro Azuma; Kazuhiro Ikeda; Ikuko Sugitani; Keiichi Kinowaki; Takeshi Fujii; Akihiko Osaki; Toshiaki Saeki; Kuniko Horie-Inoue; Satoshi Inoue
Journal:  Int J Mol Sci       Date:  2017-09-08       Impact factor: 5.923

9.  Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT.

Authors:  Bin Wang; Gang Wang; Qingfeng Wang; Ziqiang Zhu; Yunqing Wang; Kangwu Chen; Huilin Yang
Journal:  Cancer Cell Int       Date:  2019-11-08       Impact factor: 5.722

10.  TRIM44 promotes cell proliferation and migration by inhibiting FRK in renal cell carcinoma.

Authors:  Yuta Yamada; Naoki Kimura; Ken-Ichi Takayama; Yusuke Sato; Takashi Suzuki; Kotaro Azuma; Tetsuya Fujimura; Kazuhiro Ikeda; Haruki Kume; Satoshi Inoue
Journal:  Cancer Sci       Date:  2020-01-20       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.